Aquestive Therapeutics leverages its PharmFilm platform to develop Anaphylm, a sublingual epinephrine film, a $1B+ market.

Application Receives FDA Authorization to Proceed RALEIGH, NORTH CAROLINA / ACCESS Newswire / October 8, 2025 / Belhaven ...

"This collaboration represents a significant milestone for Nasus Pharma and for our NS002 program," said Dan Teleman, Chief Executive Officer of Nasus Pharma. "Through this collaboration, Nasus Pharma ...

Nasus Pharma collaborates with Aptar to support development and commercialization of NS002: Tel Aviv Saturday, October 11, 2025, 12:00 Hrs [IST] Nasus Pharma Ltd, a clinical-stage ...

Instead of stabbing yourself, or someone else, in the thigh with a needle to deliver a dose of adrenaline to counter ...

The latest announcement is out from Nasus Pharma Ltd. ( (NSRX) ).

New patents extend protection for Anaphylm™ into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe ...

Doorbell footage captured the emotional moment two young siblings comforted each other after helping save their mother’s life. Sarah James, 35, from Gillette, Wyoming, collapsed from a severe allergic ...

Immunologist Daniel Davis wants to eradicate long-held myths and replace them with wonder at the complexity of the body’s ...

The management of urticaria is often left to allergists, but the exceptional diagnostic delay in skin of color is one argument for dermatologists to regain the lead of a major skin disorder.

Aquestive Therapeutics (AQST) stock gains as the company secures new patents for Anaphylm, its oral allergy therapy currently under the FDA review. Read more here.

Speaking up about allergies and dietary restrictions can be hard, but the Benji Impact and campus resources are here to help.